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The recent outbreak of hand, foot and mouth
disease (HFMD) has claimed hundreds of lives in
Asia. The Chinese Center for Disease Control and
Prevention (China CDC) has confirmed that the
HFMD outbreak peaked on May 14, 2008. China’s
HFMD cases had reached over 60,000 with 40 fatal
cases by May 16, 2008 (Xinhua News Agency). As
of July 13, 2008, the Centers for Disease Control,
R.O.C. Taiwan, (Taiwan CDC) has reported a total
of 317 confirmed severe enteroviral cases this year,
including 10 deaths.1 The Center for Disease Con-
trol of the United States (US CDC) issued a trav-
elers’ health alert in July to warn people visiting
China, Hong Kong, Singapore and Taiwan to take
preventive measures including good personal 
hygiene and safe food and water practices.
In 1998, Taiwan experienced the largest out-
break of enterovirus (EV) 71 recorded in history,
with 129,106 cases reported and 405 children
with severe complications, 78 of whom died.2
The other EV71 outbreaks occurred in 2000 and
2001: there were 291 severe enteroviral cases, 41 of
whom died in 2000, and 393 severe enteroviral
cases including 58 fatal cases in 2001.3,4
What is HFMD and Why Is It So Deadly?
HFMD can be caused by EV71 or coxsackievirus
A16 (CA16), but the epidemics during which there
were many severe and fatal cases were largely
caused by EV71, which have been spreading in
countries throughout the Asia-Pacific region for
more than a decade. Because the virus is mainly
spread by contact with the body fluids of infected
persons, the increase in population worldwide has
ensured frequent outbreaks in many high popula-
tion density areas. Infection with EV71 can be dead-
ly in immune naïve or compromised individuals,
most often affecting young children and infants
who have not been previously exposed to the virus.
EV71 was first isolated in California in 1969.5
It can cause severe complications, including
meningitis, encephalitis, pulmonary edema and
poliomyelitis-like paralysis.6 There is as yet no ef-
fective vaccine to prevent its infection. Medical
treatment aims to target the complications rather
than the virus itself. Without an effective antivi-
ral treatment, patients must rely on their own
immune system to overcome the infection.
Besides Increasing Surveillance and Waiting for
an Effective Vaccine to Emerge in the Future,
What Else Can Be Done to Save the Lives of
HFMD Victims?
Lung-Ji Chang,1 Luan-Yin Chang,2 Li-Min Huang2*
©2008 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida,
USA, and 2Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
*Correspondence to: Dr Li-Min Huang, Department of Pediatrics, National Taiwan University Hospital, 7 Chung-Shan
South Road, Taipei 100, Taiwan.
E-mail: lmhuang@ntu.edu.tw
NEWS AND PERSPECTIVES
Although EV71 infection is often self-limited,
it is recognized that the virus can trigger a fulmi-
nant neurologic inflammatory response, which
may be associated with cardiopulmonary collapse.
These severe symptoms can develop in 2–5 days
with very limited time allowed for effective treat-
ment even if any is available.
Several candidate compounds have been de-
veloped as EV71 vaccines, including formalin-
inactivated whole virus vaccine, DNA vaccine and
recombinant protein vaccine,7,8 but all require fur-
ther refinement before they can enter clinical trials.
What Can We Do to Save EV71 Victims?
Without an effective antiviral drug, EV71 victims
are left with limited options. Vaccines have limited
use for individuals who are already infected with
EV71 because of the time required for the devel-
opment of antiviral immunity to control the rapid
course of the disease. Recent success in immune
cell therapy, however, has opened a new avenue for
treating this deadly infection.
Immune cell therapy has proven to be very 
effective in targeting viral infections, such as in 
patients undergoing hematopoietic stem cell trans-
plantation to treat Epstein Barr virus (EBV) and
cytomegalovirus (CMV). Using a rapid protocol,
antigen-specific interferon-γ-producing immune
cells can be isolated within 24 hours. The proto-
col has been used successfully to treat a young
bone marrow transplant patient who developed
EBV-associated post-transplant lymphoblastoid
disease.9 Only a very small number of antigen-
specific immune cells (103 per kg body weight) are
needed for an effective antiviral response in vivo.
Therefore, it is conceivable that EV71 antigen-
specific immune cells can be isolated from patients
(even at low frequencies) or from their healthy
haploidentical relatives, and amplified in culture
for 24–48 hours. The immune cells could then be
infused into the patients and effectively control
the disease. There is little to no complication to
this approach as the immune cells applied are
highly antigen-specific and would be present at a
very low concentration.
Such a protocol should be seriously considered
for the emergency treatment of severe HFMD vic-
tims, as there is no wonder drug available to come
to the rescue in the life or death situation of an
acute EV71 infection.
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